Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.

Journal article

Glucagon-like peptide-1 (GLP-1) is an intestinally derived insulinotropic hormone currently under investigation for use as a novel therapeutic agent in the treatment of type 2 diabetes. One of several important effects of GLP-1 is on nutrient-induced pancreatic hormone release and is mediated by binding to a specific G-protein coupled receptor resulting in the activation of adenylate cyclase and an increase in cAMP generation. In the beta-cell, cAMP binds and modulates activities of both prot...

Expand abstract

Authors: Gromada, J; Brock, B; Schmitz, O; Rorsman, P

• Publication status: Published
• Journal: Basic and clinical pharmacology and toxicology
• Volume: 95
• Issue: 6
• Pages: 252-262
• Publication date: 2004-12-01
• DOI: 10.1111/j.1742-7843.2004.t01-1-pto950502.x
• EISSN: 1742-7843
• ISSN: 1742-7835
• Language: English
• Keywords: Peptide Fragments; Glucagon-Like Peptide 1; Diabetes Mellitus, Type 2; Islets of Langerhans; Insulin; Ion Channels; Humans; Glucagon; Protein Precursors; Animals; Dipeptidyl Peptidase 4; Receptors, Glucagon; Calcium; Adenosine Triphosphate; Glucose